

Linda H M Van De Burgwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2510411/publications.pdf>

Version: 2024-02-01

21
papers

359
citations

933447

10
h-index

839539

18
g-index

23
all docs

23
docs citations

23
times ranked

400
citing authors

#	ARTICLE	IF	CITATIONS
1	The Gut Microbiota: Master of Puppets Connecting the Epidemiology of Infectious, Autoimmune, and Metabolic Disease. <i>Frontiers in Microbiology</i> , 2022, 13, 902106.	3.5	7
2	Probiotics for the Management of Infectious Diseases: Reviewing the State of the Art. <i>Frontiers in Microbiology</i> , 2022, 13, 877142.	3.5	8
3	Multispecies probiotics promote perceived human health and wellbeing: insights into the value of retrospective studies on user experiences. <i>Beneficial Microbes</i> , 2021, 12, 413-430.	2.4	4
4	Market Knowledge and Stakeholder Considerations for the Biopharmaceutics Sector—Incorporating User Value and Societal Needs in Therapeutic Interventions. <i>Health</i> , 2021, 13, 1365-1395.	0.3	3
5	On the Verge of a Catastrophic Collapse? The Need for a Multi-Ecosystem Approach to Microbiome Studies. <i>Frontiers in Microbiology</i> , 2021, 12, 784797.	3.5	15
6	European General Practitioners perceptions on probiotics: Results of a multinational survey. <i>PharmaNutrition</i> , 2020, 11, 100178.	1.7	9
7	Quantity vs. quality: an assessment of the current pipeline for rabies. <i>Tropical Medicine and International Health</i> , 2020, 25, 397-407.	2.3	6
8	Blockchain-facilitated sharing to advance outbreak R&D. <i>Science</i> , 2020, 368, 719-721.	12.6	18
9	Aiming for impact: Differential effect of motivational drivers on effort and performance in knowledge valorisation. <i>Science and Public Policy</i> , 2019, 46, 747-762.	2.4	17
10	The Nagoya Protocol on Access to Genetic Resources and Benefit Sharing: Best practices for users of Lactic Acid Bacteria. <i>PharmaNutrition</i> , 2019, 9, 100158.	1.7	10
11	Overcoming challenges for designing and implementing the One Health approach: A systematic review of the literature. <i>One Health</i> , 2019, 7, 100085.	3.4	68
12	Probiotics for improving quality of life in ulcerative colitis: Exploring the patient perspective. <i>PharmaNutrition</i> , 2019, 7, 100139.	1.7	18
13	Incentives for knowledge valorisation: a European benchmark. <i>Journal of Technology Transfer</i> , 2019, 44, 1-20.	4.3	20
14	Hybrid business models for “Organ-on-a-Chip”™ technology: The best of both worlds. <i>PharmaNutrition</i> , 2018, 6, 55-63.	1.7	10
15	Towards improved process efficiency in vaccine innovation: The Vaccine Innovation Cycle as a validated, conceptual stage-gate model. <i>Vaccine</i> , 2018, 36, 7496-7508.	3.8	10
16	How ownership rights over microorganisms affect infectious disease control and innovation: A root-cause analysis of barriers to data sharing as experienced by key stakeholders. <i>PLoS ONE</i> , 2018, 13, e0195885.	2.5	35
17	A research agenda to reinforce rabies control: A qualitative and quantitative prioritization. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006387.	3.0	10
18	Accelerating microbiota product development: The Societal Impact Value Cycle as a conceptual model to shape and improve public-private valorization processes. <i>PharmaNutrition</i> , 2018, 6, 157-168.	1.7	17

#	ARTICLE	IF	CITATIONS
19	Barriers to innovation in human rabies prophylaxis and treatment: A causal analysis of insights from key opinion leaders and literature. <i>Zoonoses and Public Health</i> , 2017, 64, 599-611.	2.2	14
20	Self-Centric and Altruistic Unmet Needs for Ebola: Barriers to International Preparedness. <i>Disaster Medicine and Public Health Preparedness</i> , 2016, 10, 644-648.	1.3	7
21	A quantitative key-opinion-leader analysis of innovation barriers in probiotic research and development: Valorisation and improving the tech transfer cycle. <i>PharmaNutrition</i> , 2016, 4, 9-18.	1.7	45